Now researchers led by Professor Heinrich Leonhardt at LMU’s Biocenter andProfessor Christian Hackenberger of the Leibniz Institute for MolecularPharmacology in Berlin have developed a new strategy that permits specific chemical modification of virtually any protein more rapidly and more efficiently than was hitherto possible.
Many of the methods routinely used in the biosciences are based on the specific modification of proteins, in particular antibodies, to endow them with novel properties for specific purposes.
Chemotherapeutic agents used in the treatment of cancer are often chemically linked to antibodies that recognize antigens found only on the surface of the target tumor.
Ideally, the methods used to introduce such modifications should be as specific,efficient and versatile as possible.
The techniques currently in use fulfill these criteria only in part.
Guide sequence integrated The new method is the first to make use of the enzyme tubulin-tyrosine ligase and its target sequence.
Adaptor for attachment of reactive agents Since the engineered nanobodies are now recognized as targets by TTL, the enzyme can also be used to attach synthetic derivatives of tyrosine to them.